Cimzia (Crohns Disease) – Forecast and Market Analysis to 2022

JULY 13TH, 2015 MARKET RESEARCH STORE

Market Research report On “Cimzia (Crohns Disease) – Forecast and Market Analysis to 2022” is a professional and Deep research report in this field

The Crohns disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira’s Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

UCB’s Cimzia (certolizumab pegol) is a PEGylated Fab’ fragment of a humanized mAb with specificity for human TNF-?. The Fab’ fragment of this biologic was engineered with a single free cysteine residue in the hinge region, which enables The site-specific attachment of polyethylene glycol without affecting the ability of the Fab’ fragment to bind to and neutralize TNF-?. Due to the absence of the Fc region in its structure, Cimzia does not cause antibody-dependent, cell-mediated cytotoxicity. Also, in contrast to Remicade and Humira, Cimzia does not increase apoptosis, a well-known phenomenon with other anti-TNF-? agents, which may be responsible for their associated side effects.

Visit Complete Report : http://www.marketresearchstore.com/report/cimzia-forecast-and-market-analysis-19630

Scope

Overview of Crohn’s disease (CD), including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on Cimzia including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Cimzia for the top seven countries from 2012 to 2022.
Sales information covered for the US, France, Germany, Italy, Spain, China and Canada

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Crohn’s disease
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of Cimzia performance
Obtain sales forecast for Cimzia from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, China and Canada)

Get Sample Copy of Report : http://www.marketresearchstore.com/report/cimzia-forecast-and-market-analysis-19630#requestSample

About Us:

MarketResearchStore.com is a single destination for all the industry, company and country reports. We feature large repository of latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations.